Antiepileptic Effect and Safety Profile of Rapamycin in Pediatric Patients With Tuberous Sclerosis Complex

BACKGROUND: Epilepsy develops in 70–90% of children with Tuberous Sclerosis Complex (TSC) and is often resistant to medication. Treatment with mTOR pathway inhibitors is an important therapeutic option in drug-resistant epilepsy associated with TSC. Our study evaluated the antiepileptic effect of ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Sadowski, Krzysztof, Sijko, Kamil, Domańska-Pakieła, Dorota, Borkowska, Julita, Chmielewski, Dariusz, Ulatowska, Agata, Józwiak, Sergiusz, Kotulska, Katarzyna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100395/
https://www.ncbi.nlm.nih.gov/pubmed/35572924
http://dx.doi.org/10.3389/fneur.2022.704978

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100395/
https://www.ncbi.nlm.nih.gov/pubmed/35572924
http://dx.doi.org/10.3389/fneur.2022.704978

Ejemplares similares